C. Gillies O'Bryan-Tear

Alpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer

Chris Parker, Sten Nilsson, Daniel Heinrich et al. · New England Journal of Medicine · 2013 · 3.3K citations

Medicine, Nuclear Medicine, Radiation Oncology +17

Effect of radium-223 dichloride on symptomatic skeletal events in patients with castration-resistant prostate cancer and bone metastases: results from a phase 3, double-blind, randomised trial

Oliver Sartor, Robert L. Coleman, Sten Nilsson et al. · The Lancet Oncology · 2014 · 491 citations

Medicine, Oncology, Pharmacology +17

Two-Year Survival Follow-Up of the Randomized, Double-Blind, Placebo-Controlled Phase II Study of Radium-223 Chloride in Patients With Castration-Resistant Prostate Cancer and Bone Metastases

Sten Nilsson, Lars Franzén, Christopher Parker et al. · Clinical Genitourinary Cancer · 2012 · 119 citations

Medicine, Oncology, Radiation Oncology +17

Overall survival benefit and safety profile of radium-223 chloride, a first-in-class alpha-pharmaceutical: Results from a phase III randomized trial (ALSYMPCA) in patients with castration-resistant prostate cancer (CRPC) with bone metastases.

Chris Parker, Daniel Heinrich, Joe M. O’Sullivan et al. · Journal of Clinical Oncology · 2012 · 98 citations

Medicine, Oncology, Pharmacology +17

Updated analysis of the phase III, double-blind, randomized, multinational study of radium-223 chloride in castration-resistant prostate cancer (CRPC) patients with bone metastases (ALSYMPCA).

Chris Parker, Sten Nilsson, Daniel Heinrich et al. · Journal of Clinical Oncology · 2012 · 76 citations

Medicine, Oncology, Radiation Oncology +17